IN2014DN08398A - - Google Patents

Info

Publication number
IN2014DN08398A
IN2014DN08398A IN8398DEN2014A IN2014DN08398A IN 2014DN08398 A IN2014DN08398 A IN 2014DN08398A IN 8398DEN2014 A IN8398DEN2014 A IN 8398DEN2014A IN 2014DN08398 A IN2014DN08398 A IN 2014DN08398A
Authority
IN
India
Prior art keywords
biomarker
parkinson
disease
drug
relates
Prior art date
Application number
Other languages
English (en)
Inventor
Dario Alessi
Muratul Muqit
Original Assignee
Univ Dundee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Dundee filed Critical Univ Dundee
Publication of IN2014DN08398A publication Critical patent/IN2014DN08398A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IN8398DEN2014 2012-04-11 2013-04-10 IN2014DN08398A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201206382A GB201206382D0 (en) 2012-04-11 2012-04-11 Parkinson's disease biomarker
PCT/GB2013/050926 WO2013153386A1 (en) 2012-04-11 2013-04-10 Parkinson's disease biomarker

Publications (1)

Publication Number Publication Date
IN2014DN08398A true IN2014DN08398A (ja) 2015-05-08

Family

ID=46177150

Family Applications (1)

Application Number Title Priority Date Filing Date
IN8398DEN2014 IN2014DN08398A (ja) 2012-04-11 2013-04-10

Country Status (5)

Country Link
US (1) US20150104806A1 (ja)
EP (1) EP2836842A1 (ja)
GB (1) GB201206382D0 (ja)
IN (1) IN2014DN08398A (ja)
WO (1) WO2013153386A1 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015125702A1 (ja) * 2014-02-18 2015-08-27 公益財団法人東京都医学総合研究所 パーキンソン病のバイオマーカーおよびその利用
EP3288963B1 (en) * 2015-05-01 2020-12-23 Wo, Andrew Man Chung Pink1 c-terminal domain polypeptide and methods using the same in cancer treatment
GB201516342D0 (en) * 2015-09-15 2015-10-28 Univ Dundee Downstream targets of PINK1
US11360102B2 (en) 2015-09-23 2022-06-14 Boston Medical Center Corporation Biomarkers for the early detection of Parkinson's disease
EP3661413A1 (en) * 2017-08-01 2020-06-10 Cove Bio LLC Biomarkers associated with parkinson's disease
WO2020187104A1 (zh) * 2019-03-19 2020-09-24 中南大学湘雅医院 一种辅助诊断和治疗帕金森病的方法和试剂

Also Published As

Publication number Publication date
US20150104806A1 (en) 2015-04-16
EP2836842A1 (en) 2015-02-18
WO2013153386A1 (en) 2013-10-17
GB201206382D0 (en) 2012-05-23

Similar Documents

Publication Publication Date Title
WO2013066764A3 (en) Alzheimer's disease signature markers and methods of use
IN2014DN08398A (ja)
NZ735173A (en) Biomarkers for the diagnosis and/or prediction of susceptibility to mental and neurodegenerative disorders
IL245176A0 (en) Biomarkers and methods for diagnosing Alzheimer's and other neurodegenerative diseases
EP3464638A4 (en) USE OF BIOMARKERS TO DETERMINE SENSITIVITY TO TREATMENT OF A DISEASE
WO2015094995A3 (en) Gene signature biomarkers of tumor response to pd-1 antagonists
WO2014140254A9 (en) Improved user interface for acquistion, display and analysis of ophthalmic diagnostic data
WO2013192274A3 (en) Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy
IL246917A0 (en) Biomarker and early diagnosis methods for Alzheimer's disease
BR112013010015A2 (pt) aparelho e método para detecção não invasiva de doenças que afetam as propriedades estruturais em tecidos biológicos
BR112013022493A2 (pt) equipamento e método para examinar, diagnosticar ou auxiliar no diagnóstico e no tratamento de problemas funcionais de visão
MX358474B (es) Biomarcadores salivales específicos para detección de riesgo, diagnóstico temprano, pronóstico y vigilancia de las enfermedades de alzheimer y de parkinson.
WO2012173976A3 (en) Methods and apparatus for assessing activity of an organ and uses thereof
BR112016004305A2 (pt) métodos diagnósticos e composições para tratamento de glioblastoma
WO2015013508A3 (en) Methods for diagnosing and treating immune disease
AP2015008366A0 (en) 2-Phenyl-5-heterocyclyl-tetrahydro-2H-pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders
BR112014014960A2 (pt) métodos para o diagnóstico da doença de alzheimer
NZ716643A (en) Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event
NZ729773A (en) Biomarkers for disease progression in melanoma
IN2014DN08537A (ja)
PH12017502099A1 (en) Methods for diagnosing and assessing treatment for cushing's syndrome
MX2017001293A (es) Metodos y composiciones para diagnosticar y tratar trastornos inflamatorios del intestino.
BR112015027249A2 (pt) método de diagnóstico de câncer
WO2014052685A3 (en) Devices and methods for single cell analysis
MX2015017535A (es) Tratamiento de resistencia a la insulina a traves de inhibidores del factor de transcripcion tsc22d4.